Coloplast A/S
CSE:COLO B

Watchlist Manager
Coloplast A/S Logo
Coloplast A/S
CSE:COLO B
Watchlist
Price: 891.6 DKK 2.11% Market Closed
Market Cap: 200.6B DKK
Have any thoughts about
Coloplast A/S?
Write Note

Intrinsic Value

The intrinsic value of one COLO B stock under the Base Case scenario is 877.42 DKK. Compared to the current market price of 891.6 DKK, Coloplast A/S is Overvalued by 2%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

COLO B Intrinsic Value
877.42 DKK
Overvaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Coloplast A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for COLO B cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about COLO B?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Coloplast A/S

Provide an overview of the primary business activities
of Coloplast A/S.

What unique competitive advantages
does Coloplast A/S hold over its rivals?

What risks and challenges
does Coloplast A/S face in the near future?

Summarize the latest earnings call
of Coloplast A/S.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Coloplast A/S.

Provide P/S
for Coloplast A/S.

Provide P/E
for Coloplast A/S.

Provide P/OCF
for Coloplast A/S.

Provide P/FCFE
for Coloplast A/S.

Provide P/B
for Coloplast A/S.

Provide EV/S
for Coloplast A/S.

Provide EV/GP
for Coloplast A/S.

Provide EV/EBITDA
for Coloplast A/S.

Provide EV/EBIT
for Coloplast A/S.

Provide EV/OCF
for Coloplast A/S.

Provide EV/FCFF
for Coloplast A/S.

Provide EV/IC
for Coloplast A/S.

Show me price targets
for Coloplast A/S made by professional analysts.

What are the Revenue projections
for Coloplast A/S?

How accurate were the past Revenue estimates
for Coloplast A/S?

What are the Net Income projections
for Coloplast A/S?

How accurate were the past Net Income estimates
for Coloplast A/S?

What are the EPS projections
for Coloplast A/S?

How accurate were the past EPS estimates
for Coloplast A/S?

What are the EBIT projections
for Coloplast A/S?

How accurate were the past EBIT estimates
for Coloplast A/S?

Compare the revenue forecasts
for Coloplast A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Coloplast A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Coloplast A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Coloplast A/S compared to its peers.

Compare the P/E ratios
of Coloplast A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Coloplast A/S with its peers.

Analyze the financial leverage
of Coloplast A/S compared to its main competitors.

Show all profitability ratios
for Coloplast A/S.

Provide ROE
for Coloplast A/S.

Provide ROA
for Coloplast A/S.

Provide ROIC
for Coloplast A/S.

Provide ROCE
for Coloplast A/S.

Provide Gross Margin
for Coloplast A/S.

Provide Operating Margin
for Coloplast A/S.

Provide Net Margin
for Coloplast A/S.

Provide FCF Margin
for Coloplast A/S.

Show all solvency ratios
for Coloplast A/S.

Provide D/E Ratio
for Coloplast A/S.

Provide D/A Ratio
for Coloplast A/S.

Provide Interest Coverage Ratio
for Coloplast A/S.

Provide Altman Z-Score Ratio
for Coloplast A/S.

Provide Quick Ratio
for Coloplast A/S.

Provide Current Ratio
for Coloplast A/S.

Provide Cash Ratio
for Coloplast A/S.

What is the historical Revenue growth
over the last 5 years for Coloplast A/S?

What is the historical Net Income growth
over the last 5 years for Coloplast A/S?

What is the current Free Cash Flow
of Coloplast A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Coloplast A/S.

Business Breakdown

Coloplast A/S is a leading global healthcare company headquartered in Denmark, dedicated to the development of innovative medical devices and solutions for individuals with intimate healthcare needs. Founded in 1954, the company has a strong heritage built on empathy and understanding of patient challenges, which drives its continuous commitment to enhancing the quality of life for people with chronic conditions. Coloplast operates in three primary business areas: ostomy care, urology, and continence care, crafting products that empower individuals to manage their health effectively. With a presence in over 40 countries and products sold in more than 100 markets, Coloplast not only boasts a...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Coloplast A/S

Current Assets 10.4B
Cash & Short-Term Investments 788m
Receivables 5.6B
Other Current Assets 4.1B
Non-Current Assets 37.6B
Long-Term Investments 74m
PP&E 6.6B
Intangibles 30.3B
Other Non-Current Assets 652m
Current Liabilities 10.2B
Accounts Payable 1.5B
Accrued Liabilities 7m
Other Current Liabilities 8.7B
Non-Current Liabilities 19.9B
Long-Term Debt 17.3B
Other Non-Current Liabilities 2.6B
Efficiency

Earnings Waterfall
Coloplast A/S

Revenue
27B DKK
Cost of Revenue
-8.8B DKK
Gross Profit
18.3B DKK
Operating Expenses
-11B DKK
Operating Income
7.3B DKK
Other Expenses
-2.2B DKK
Net Income
5.1B DKK

Free Cash Flow Analysis
Coloplast A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

The company kicked off the year maintaining their guidance with an organic revenue growth target of around 8%. They anticipate consistent progress throughout the year across various businesses and locations, except China. While previously forecasting a revenue growth of roughly 12% in Danish kroner, currency impacts have led them to adjust the expectation to approximately 11%. The report also suggests a steady contribution from Kerecis, projecting about 4 percentage points to the overall revenue growth. The EBIT margin before special items is expected to remain between 27% to 28%.

What is Earnings Call?
Fundamental Scores

COLO B Profitability Score
Profitability Due Diligence

Coloplast A/S's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Free Cash Flow
Positive Operating Income
67/100
Profitability
Score

Coloplast A/S's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

COLO B Solvency Score
Solvency Due Diligence

Coloplast A/S's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
52/100
Solvency
Score

Coloplast A/S's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

COLO B Price Targets Summary
Coloplast A/S

There are no price targets for COLO B.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for COLO B?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Nov 24, 2024
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for COLO B is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Coloplast A/S Logo
Coloplast A/S

Country

Denmark

Industry

Health Care

Market Cap

200.9B DKK

Dividend Yield

2.36%

Description

Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.

Contact

Humlebaek
Holtedam 1-3
+4549111111.0
www.coloplast.dk

IPO

1983-01-01

Employees

12 500

Officers

President & CEO
Mr. Kristian Villumsen
Executive VP & CFO
Mr. Anders Lonning-Skovgaard
Executive Vice President of Global Operations
Mr. Allan Rasmussen
Executive Vice President of Innovation
Mr. Nicolai Buhl Andersen
Executive Vice President of Growth
Mr. Paul Marcun
Senior Controller & Employees Representative Director
Mr. Thomas Barfod
Show More
Vice President of Investor Relations
Ellen Bjurgert
Director of Corporate Communications
Dennis Kaysen
Senior Vice President of People & Culture
Dorthe Ronnau
Senior Vice President of Sales Europe
Mr. Alain Morvan
Show Less

See Also

Discover More
What is the Intrinsic Value of one COLO B stock?

The intrinsic value of one COLO B stock under the Base Case scenario is 877.42 DKK.

Is COLO B stock undervalued or overvalued?

Compared to the current market price of 891.6 DKK, Coloplast A/S is Overvalued by 2%.

Back to Top